Navigation Links
Marinus Pharmaceuticals Announces U.S. Department of Defense Grant to Study Ganaxolone in Fragile-X Syndrome
Date:4/13/2011

NEW HAVEN, Conn., April 13, 2011 /PRNewswire/ -- Marinus Pharmaceuticals, Inc., the leader in the development of neurosteroids for central nervous system disorders, today announced the award of a $3 million grant by the U.S. Department of Defense to study its lead candidate ganaxolone for the treatment of Fragile-X Syndrome (FXS). Ganaxolone modulates GABA-A ion channels by selective binding to the neurosteroid receptor. Early research suggests that normalizing neurosteroid levels with ganaxolone treatment may eliminate the behavioral symptoms associated with FXS.

The $3 million federal grant was awarded to three University of California, Davis (UCD) researchers: Randi Hagerman, M.D., an international authority on Fragile X-related disorders; Michael Rogawski, M.D., Ph.D., a world-renowned epilepsy researcher; and David Hessl, Ph.D., an expert in psychophysiology studies. The group will enroll 60 children between the ages of six and 17 years to study the safety and effectiveness of ganaxolone for treating behaviors and anxiety common with FXS.

"The fact that a study with ganaxolone was awarded this grant is a testament to the potential for neurosteroid augmentation as a new treatment for FXS patients," stated Gail Farfel, Ph.D., Chief Clinicaland Regulatory Officer of Marinus. "The scientific data suggests that ganaxolone may be ideally suited to reverse FXS symptoms related to the down-regulation of the neurosteroid binding site on GABA-A ion channels."

"Over the next few months, we will work with UCD to provide ganaxolone for the FXS study and work on obtaining regulatory approval from the Food and Drug Administration to allow the researchers to conduct this study under Marinus' Investigational New Drug Application," commented Kenneth Shaw, Ph.D., Senior Vice President, R&D at Marinus.

About Ganaxolone

Ganaxolone is a synthetic neurosteroid and a derivative of the naturally occurring neuromodulator, allopregnanolone.  Ganaxolone has been administered to more than 950 healthy adult volunteers and patients in Phase 1 and Phase 2 studies. Completed Phase II epilepsy studies have generated data supportive of the efficacy and safety of ganaxolone in the treatment of both children and adults suffering from refractory epilepsy (patients who continue to have seizures despite taking multiple anticonvulsant drugs). Scientific research has suggested that ganaxolone therapy may be useful in the treatment of several other central nervous system disorders including posttraumatic stress disorder (PTSD) and Fragile-X Syndrome (FXS). Ganaxolone is being developed as a first in class treatment in epilepsy, PTSD and FXS.

Marinus has successfully developed several proprietary and novel patented formulations of ganaxolone.

About Fragile-X Syndrome

The result of a defect on the X chromosome, Fragile-X Syndrome (FXS) is the leading cause of inherited mental disability and the most common single-gene cause of autism. The condition is estimated to affect one in 3,600 males and one in 4,000 females. Approximately one-third of all children diagnosed with Fragile-X Syndrome also have some degree of autism. Fragile-X symptoms include learning and memory impairment, anxiety, hyperactivity and social avoidance.  Up to 30% of people with Fragile-X also develop seizures.

About Marinus Pharmaceuticals

Marinus is a specialty pharmaceutical company dedicated to the reformulation, development, and commercialization of novel drugs to treat serious neurological and psychiatric disorders. Marinus is located in Branford, Connecticut. Its investors include Domain Associates, Canaan Partners, Sofinnova Ventures and Foundation Medical Partners. For additional information, please visit the company's Web site at www.marinuspharma.com.


'/>"/>
SOURCE Marinus Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Marinus Pharmaceuticals Issued Patent for Ganaxolone
2. Conatus Pharmaceuticals Completes the Second Closing of its Series B Private Placement Financing
3. MAP Pharmaceuticals to Present Data From LEVADEX® Pharmacokinetics and Pharmacodynamics Safety Studies at the 63rd Annual Meeting of the American Academy of Neurology
4. Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
5. Valeant Pharmaceuticals Files Presentation for Cephalon Stockholders
6. Webcast and Conference Call Alert: Isis Pharmaceuticals Holds Webcast to Discuss Recent Advances in its Development Pipeline
7. Auxilium Pharmaceuticals, Inc. Announces Launch of XIAPEX® in EU by Pfizer
8. Vanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt®
9. Idenix Pharmaceuticals Prices Public Offering of Common Stock
10. Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
11. Idenix Pharmaceuticals Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
(Date:4/19/2017)...  IRIDEX Corporation (Nasdaq: IRIX ) today ... first quarter 2017 after the close of trading on ... host a corresponding conference call beginning at 2:30 p.m. ... in listening to the conference call may do so ... 326-3030 for international callers, using conference ID: 92158987.  A ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... 2017 , ... Providing broad access to life-saving drugs and rewarding the innovators ... way to address this problem. , That was the message from Dana Goldman, PhD, ... the University of Southern California, who served as the keynote speaker for Western University ...
(Date:4/21/2017)... ... April 21, 2017 , ... Chicago plastic surgeon, Dr. Anil R. ... osteoma is a benign bony lump located on the forehead usually attributed to a ... with sight and pain. Dr. Shah has discovered an approach that is minimally invasive. ...
(Date:4/21/2017)... PA (PRWEB) , ... April 21, 2017 , ... ... firm in Allegheny County that offers services to communities throughout the greater Pittsburgh ... in a charity drive to provide adaptive bicycles for differently-abled children. , Variety ...
(Date:4/21/2017)... ... April 21, 2017 , ... The Patient Advocacy Community of The ... the 2017 Ruth Ravich Patient Advocacy Award in recognition of her extraordinary ... honored with the award at The Beryl Institute’s annual Patient Experience Conference ...
(Date:4/21/2017)... ... 21, 2017 , ... Crossover Symmetry , an evidence ... active lifestyle company that provides Human Performance Training and education to tactical athletes. ... responders, military officers and others in service through the development and conditioning of ...
Breaking Medicine News(10 mins):